This article is more than 5 years old. Information may no longer be current.
VIDEO: More research needed on side effects of SGLT2 inhibitors in patients with diabetes
NEW ORLEANS — More research is needed on the use of SGLT2 inhibitors in patients with diabetes given the potential risk for diabetic ketoacidosis and bone fractures, according to Rodica Busui, MD, PhD, of the University of Michigan Health System.
In this video, Busui discusses the increased interest in the potential benefits – as well as associated risk factors – of using SGLT2 inhibitors in patients with diabetes, to not only lower glucose, but also reduce cardiovascular death, blood pressure and other heart failure-related endpoints, as well as potentially protect against the development of chronic kidney disease.
Busui highlights a session at the American Diabetes Association annual meeting that demonstrated an increased risk for bone fractures in patients.
“[These agents] are clearly required to be explored further to understand whether there is a class effect versus [a] drug-specific effect,” she said.
Busui also mentions that more research is needed on the possible effects in patients with type 1 diabetes.
“Much more research needs to be done given the potential risk for [diabetic ketoacidosis] that had also been unveiled by two independent groups of investigators through the potential effect on insulin dose reduction and the subsequent effects on glucagon and ketogenesis.”